South San Francisco-based Genentech, the U.S. unit of Switzerland-based drug giant Roche, said today it has been granted a hearing in which it will get a chance to appeal the FDA’s decision to revoke the market approval of bevacizumab (Avastin) for women with breast cancer. The company will be able to make its case June 28 and 29. The drug is cleared for sale by the FDA to fight lung and colorectal cancers, and it will remain cleared for sale as a treatment for breast cancer until the FDA appeal process is complete, Genentech said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
